Clinical Study
CT-Guided 125I Seed Interstitial Brachytherapy as a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy
Table 1
Patient (
) and tumor (
) characteristics.
| | Parameter | Number of patients (%) |
| | Gender | | | Male | 14 (58.3%) | | Female | 10 (41.6%) | | Median age (range) | 59 (31–77) | | Primary tumor | | | Lung cancer | 6 (25.0%) | | Liver carcinoma | 5 (20.8%) | | Renal carcinoma | 4 (16.7%) | | Colorectal cancer | 2 (8.3%) | | Others | 7 (29.2%) | | Level of spinal | | | Cervical | 3 (11.5%) | | Thoracic | 12 (46.2%) | | Lumbar | 10 (38.5%) | | Sacral | 1 (3.8%) | | Number of spine metastases | | | 1 | 22 (91.7%) | | 2 | 2 (8.3%) | | NRS pain score | | | 1–3 | 8 (33.3%) | | 4–6 | 12 (50.0%) | | 7–10 | 4 (16.7%) | | Neurologic symptoms | | | Yes | 9 (37.5%) | | No | 15 (62.5%) | | KPS | | | Median (range) | 80 (60–90) | | Preseed implant | | | Surgery + EBRT + CTx | 9 (34.6%) | | Surgery + EBRT | 4 (15.4%) | | EBRT + CTx | 6 (23.1%) | | EBRT | 7 (26.9%) | | Time between EBRT and 125I implant (months) | | | Median (range) | 6 (6–36) | | Prior EBRT total dose/number of fractions | | | 30 Gy/10 fraction | 5 (20.8%) | | 38 Gy/19 fraction | 2 (8.3%) | | 40–48 Gy/12–21 fraction | 8 (33.3%) | | 50–54 Gy/20–30 fraction | 5 (20.8%) | | 60 Gy/20 fraction | 3 (12.5%) | | 60 Gy/25 fraction | 1 (4.2%) | | Prior of spinal cord (Gy) | | | Median (range) | 35 (11.6–45.7) |
|
|
NRS = numeric rating scale; KPS = Karnofsky performance score; EBRT = external beam radiotherapy; CTx = chemotherapy.
of treatment lesions.
|
